Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g., ischemic/reperfused), but not in the h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cells
Main Authors: Brenner, Gábor B., Makkos, András, Nagy, Csilla Terézia, Onódi, Zsófia, Sayour, Nabil V., Gergely, Tamás G., Kiss, Bernadett, Görbe, Anikó, Sághy, Éva, Zádori, Zoltán S., Lázár, Bernadette, Baranyai, Tamás, Varga, Richárd S., Husti, Zoltán, Varró, András, Tóthfalusi, László, Schulz, Rainer, Baczkó, István, Giricz, Zoltán, Ferdinandy, Péter
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7140447/
https://ncbi.nlm.nih.gov/pubmed/32111102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030551
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados